Results 41 to 50 of about 107,800 (308)
Mesothelioma in Scotland [PDF]
BMJ, 1970 In a retrospective study of the incidence of mesothelioma in Scotland for 1950-67 80 cases were traced from pathological reports and biopsy material of malignant tumours invading the pleura and peritoneum. These cases were matched with two sets of controls.
A. A. M. Gibson +3 more
openaire +3 more sources
Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening [PDF]
, 2017 Introduction: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a programme could maximise access
Blyth, Kevin G. +2 more
core +1 more source
A comparison of the results from intra-pleural and intra-peritoneal studies with those from inhalation and intratracheal tests for the assessment of pulmonary responses to inhalable dusts and fibres. [PDF]
, 2016 The aim of this paper is to compare results from inhalation studies with those from intraperitoneal and intrapleural tests, where available, for a number of fibrous and particulate test materials.
Bevan, Ruth +2 more
core +2 more sources
Journal of the Royal Society of Medicine, 1989 Mesothelioma is a malignant tumour of the pleura or peritoneum caused by asbestos. It is increasing in frequency and the prognosis remains grim, with average survival around 1 year.Medical literature and personal experience.Amphibole fibres are far more potent than chrysotile in causing mesothelioma.A minority view suggests that mesotheliomas in those ...
openaire +4 more sources
Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy [PDF]
, 2018 Introduction: Pleural Malignancy (PM) is often occult on subjective radiological assessment. We sought to define a novel, semi-objective Magnetic Resonance Imaging (MRI) biomarker of PM, targeted to increased tumour microvessel density (MVD) and ...
Alexander, Laura +10 more
core +1 more source
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]
, 2018 SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L. +11 more
core +2 more sources
BMJ OpenObjectives Mesothelioma is an aggressive cancer predominantly affecting the lung and abdominal linings. It can have a unique impact on mental health and well-being (MHWB) due to its incurability, poor prognosis and asbestos-exposure causation.
Clare Gardiner +5 more
doaj +1 more source
Changing Pattern in Malignant Mesothelioma Survival
Translational Oncology, 2015 Survival for mesothelioma has been shown to be poor, with marginal improvement over time. Recent advances in the understanding of pathophysiology and treatment of mesothelioma may impact therapy to improve survival that may not be evident from available ...
Jennifer Faig +5 more
doaj +1 more source
Insights into Imaging, 2021 The peritoneal cavity is the second commonest site of mesothelioma after the pleural cavity. There are five histological types of peritoneal mesothelioma with variable symptomatology, clinical presentation and prognosis.
Anuradha Chandramohan +6 more
doaj +1 more source
In Vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma [PDF]
, 2017 Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor. The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a "multifunctional drug". Several studies have demonstrated API anti-tumoral effects.
Andrea Modesti +13 more
core +2 more sources